Catalog No.S2624 Synonyms: ASP4786

OSI-027 Chemical Structure

Molecular Weight(MW): 406.44

OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM in cell-free assays, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ or DNA-PK. Phase 1.

Size Price Stock Quantity  
In DMSO USD 200 In stock
USD 120 In stock
USD 210 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 16 Publications

6 Customer Reviews

  • Urol Oncol 2013 1078-1439(13)00251-2. OSI-027 purchased from Selleck.

  • Cells were treated during 7 days with OSI-027 (C, D). Response is expressed as the percentage of vehicle-treated control (±s.e.m.). Control is normalised at 100%.

    Br J Cancer, 2016, 114(6):650-8. OSI-027 purchased from Selleck.

  • Cell Physiol Biochem, 2018, 46(2):676-686. OSI-027 purchased from Selleck.

  • H460 and A549 cells were treated with 20 μM OSI-027 for the indicated amount of time. Protein levels were estimated using western blot analysis. The blot shown is representative of 3 independent experiments

    Sci Rep, 2016, 6:28945. OSI-027 purchased from Selleck.

  • HCC cell lines (HepG2 and SMMC-7721) or the primary human HCC cells (“HCC-1/-2”) were treated with AT406 (at applied concentrations) or plus OSI-027 (“OSI”, 100 nM), cells were further cultured for indicated periods of time, the caspase-3 activity (A, for HepG2 cells) was tested; Cell apoptosis was tested by the ssDNA ELISA assay (B, F–H) or the TUNEL staining assay (C, for HepG2 cells). HepG2 cells were pretreated with the caspase-3 specific inhibitor z-DEVD-fmk (50 μM) or the general caspase inhibitor z-VAD-fmk (50 μM) for 1 hour, followed by AT406 (10 μM) plus OSI-027 (100 nM) combination treatment (“Both”), cells were further cultured and subjected to ssDNA ELISA assay of apoptosis (D) and MTT assay of cell viability (E). “Veh” stands for 0.2% of DMSO (D and E). *indicated statistically significant differences as compared to “Ctrl” group. #indicated statistically significant differences as compared to “AT406” only group (A–C, F–H). ##indicated statistically significant differences as compared to “Both” group (D and E).

    Oncotarget, 2017, 8(6):9466-9475. OSI-027 purchased from Selleck.

  • EdU staining of GBC-SD cells treated with OSI-027 (6.25 μM) and/or 5-FU (6.25 μg/mL) was performed by using Click-iT EdU Imaging Kit. The percentages of EdU-positive cells have been provided in the right panel.

    Eur Rev Med Pharmacol Sci, 2016, 20(9):1699-706.. OSI-027 purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM in cell-free assays, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ or DNA-PK. Phase 1.
mTOR [4]
(Cell-free assay)
mTORC1 [1]
(Cell-free assay)
mTORC2 [1]
(Cell-free assay)
PI3Kγ [4]
(Cell-free assay)
4 nM 22 nM 65 nM 0.42 μM
In vitro

OSI-027 shows the selective and ATP competitive inhibition activities against mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively. In addition, OSI-027 inhibits mTOR signaling of phospho-4E-BP1 with an IC50 of 1 μM in cell-based assays. [1] OSI-027 exhibits anti-proliferative activities against several acute leukemia cell lines of myeloid/megakaryocytic origin in a dose-dependent manner, including U937, KG-1, KBM-3B, ML-1, HL-60, and MEG-01 cells. [2] A recent study shows that inhibition of mTORC1/2 by OSI-027 effectively suppresses phosphorylation of Akt (S473) and cell proliferation in breast cancer cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human SQ20B cells NH[wT5BEgXSxdH;4bYNqfHliYYPzZZk> Mnq3O|IhcA>? MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTVVIxSiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuN{DPxE1? M3vCeFI1PDR3M{Gx
human Caki1 cells NWPn[pZES3m2b4TvfIlkcXS7IHHzd4F6 MkiwO|IhcA>? NXOxSnNuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS2GtaUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yNjlizszN M{jpSVI1PDR3M{Gx
human SKHEP1 cells NYfmTo9WS3m2b4TvfIlkcXS7IHHzd4F6 MVu3NkBp NXjHR5NIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uKRWCxJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:Oy5{IN88US=> MlnxNlQ1PDV|MUG=
human DU145 cells MU\DfZRwfG:6aXPpeJkh[XO|YYm= NU\BSpRZPzJiaB?= MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUSuNUDPxE1? M1nXXVI1PDR3M{Gx
human HCT116 cells Ml;RR5l1d3SxeHnjbZR6KGG|c3H5 Ml;SO|IhcA>? MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21MlYh|ryP M2njZVI1PDR3M{Gx
human ColoR cells NUf6Nm1uS3m2b4TvfIlkcXS7IHHzd4F6 NWLjSJdPPzJiaB?= NFjWemlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEd2yxUjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUvQCEQvF2= NY[zZlV1OjR2NEWzNVE>
human COLO205 cells NHy4Ro9EgXSxdH;4bYNqfHliYYPzZZk> NXTHeHBGPzJiaB?= MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OU45KM7:TR?= NWfjSo9TOjR2NEWzNVE>
human OVCAR3 cells NWXMcFJSS3m2b4TvfIlkcXS7IHHzd4F6 NV2xUHhGPzJiaB?= MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWmNCWjNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME24MlEh|ryP MoHDNlQ1PDV|MUG=
human HOP62 cells MlLXR5l1d3SxeHnjbZR6KGG|c3H5 NI\RbXI4OiCq NYj4XHdzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUE:SNkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF01OSEQvF2= MorhNlQ1PDV|MUG=
human COLO205 cells M3nQU2N6fG:2b4jpZ4l1gSCjc4PhfS=> MXq3NkBp Mom1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR29NVzJyNTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6 MViyOFg{PjB5MB?=
human HOP62 cells M{TSNmN6fG:2b4jpZ4l1gSCjc4PhfS=> MkPsO|IhcA>? MlHwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTG9RPjJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfS=> M2PQVFI1QDN4MEew

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
p-mTOR / mTOR / p-AKT / AKT / p-P70S6K / P70S6K / p-4EBP1 / 4EBP1 ; 

PubMed: 26026051     

Immunoblot analysis of mTORC1 and mTORC2 signaling in Huh-7 cells treated with 4 µmol/L rapamycin (Rapa) or various concentrations of OSI-027 for 8 hours.


PubMed: 24610825     

U937 cells were treated with OSI-027 for 24 hours and after collection were stained with anti-DAPI (blue) or anti-LC3 (green) and signals were detected by confocal microscopy. Merged panels indicate areas of overlapping images of the two fluorescing signals.

Growth inhibition assay
Cell viability; 

PubMed: 25823922     

(A) U937, (B) MM6, (C) Kasumi-1 cells were plated in 96 well plates and treated with BYL-719 and OSI-027 alone and in combination, as indicated, for 72 hours. Viability was assessed using a WST-1 assay. Data are expressed as percentage of vehicle-treated cells (control). Shown are means and standard errors of five (A) or four (B and C) independent experiments.

In vivo In GEO colorectal xenograft, OSI-027 (65 mg/kg) inhibits both mTORC1 and mTORC2 effectors, including 4E-BP1, Akt, and S6 phosphorylation. Furthermore, mTORC1 and mTORC2 inhibition together by OSI-027 potently inhibits tumor growth more than mTORC1 inhibition by rapamycin. [1]


Kinase Assay:


+ Expand

Biochemical assays:

mTORC1 and mTORC2 inhibition is assayed using native enzyme complex immunoprecipitated from HeLa lysates at 1 mM ATP. To prepare whole cell lysates from HeLa cells, 25 g cell pellet is lysed in 60 mL of ice-cold buffer A [40 mM HEPES (pH 7.5), 120 mM NaCl, 1 mM EDTA, 10 mM sodium pyrophosphate, 10 mM glycerophosphate, 50 mM NaF, 0.5 mM orthovanadate, and EDTA-free protease inhibitors containing 0.3% CHAPS] for 30 minutes on a magnetic stirrer in a cold room. After clearing of the lysates by centrifugation at 13,000 g for 10 minutes, Protein G-coated 384-well plates are incubated with 0.25 μg of mTOR antibody in 15 μL of buffer A for 1 hour at 4 °C. To each well, 40 μg of HeLa cell lysate in 15 μL of buffer A is added and incubated overnight at 4 °C to immunoprecipitate mTOR complexes. Plates are washed 3 times with buffer A and twice with immunoprecipitation wash buffer [Buffer B: 50 mM HEPES (pH 7.5) and 150 mM NaCl]. OSI-027 is added at 10 μM concentration to each well and DMSO is added to the control wells. The reaction is started by adding 150 ng of His-tagged 4E-BP1 as a substrate in the presence or absence of 100 μM ATP to each well in 25 μL of freshly prepared kinase buffer [Buffer C: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 4 mM MnCl2, 10 mM β-mercaptoethanol, and 200 μM vanadate] and incubated at room temperature (RT) for 30 minutes. The reaction is stopped by transferring 25 μL of reaction mixture from each well to corresponding wells of fresh Ni-chelate-coated plates and incubated overnight at 4 °C followed by 2 hours at 37 °C. To detect phosphorylation of 4E-BP1, the plates are washed once with TBST (Tris-buffered saline containing 0.1% Tween-20) containing 5% skim milk powder. To each well, 25 μL of 1:1,000 diluted phospho-4E-BP1 antibodies in TBST containing 5% skim milk are added and incubated for 1 hour at RT. The plates are washed once with TBST and then 25 μL of anti-rabbit HRP (diluted 1:10,000) in TBST containing 5% skim milk is added. The plates are incubated for 1 hour at RT and washed 5 times with TBST. For detection of phospho-4E-BP1, 25 μL of chemiluminescent reagents A+B is added and chemiluminescence is measured using an Analyst plate reader.
Cell Research:


+ Expand
  • Cell lines: U937, KG-1, KBM-3B, ML-1, HL-60, and MEG-01
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method:

    Inhibition of proliferation is measured using the Cell Titer Glo Assay , as noted in figure legends. To generate dose–response curves, cell lines are seeded at a density of 5,000 cells per well in a 96-well plate. After 24 hours of plating, cells are dosed with varying concentrations of either OSI-027 or rapamycin. The signal for Cell Titer Glo Assay is determined 72 hours after dosing and normalized to that of vehicle-treated controls. Inhibition of proliferation, relative to vehicle-treated controls, is expressed as a fraction of 1 and graphed using PRISM software.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: GEO colorectal cells are injected s.c. into the right flank of nu/nu CD-1 mice.
  • Formulation: Dissolved in DMSO and then diluted in water.
  • Dosages: ≤65 mg/kg
  • Administration: Administered via gavage.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 18 mg/mL (44.28 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 406.44


CAS No. 936890-98-1
Storage powder
in solvent
Synonyms ASP4786

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy OSI-027 | OSI-027 supplier | purchase OSI-027 | OSI-027 cost | OSI-027 manufacturer | order OSI-027 | OSI-027 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID